Ab­b­Vie's Qulip­ta adds FDA ap­proval for chron­ic mi­graine

Ab­b­Vie’s mi­graine drug Qulip­ta has net­ted FDA ap­proval for an­oth­er in­di­ca­tion.

On Tues­day, the Illi­nois phar­ma an­nounced the FDA ap­proved an ex­pand­ed in­di­ca­tion of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.